Non-Small Cell Lung Cancer

New Drug: Pralsetinib for non-small cell lung cancer with RET gene fusions

2023-06-07

  • Study

    Multicenter, open-label, multicohort phase 1/2 trial
    Locally advanced or metastatic RET fusion-positive NSCLC
    Pralsetinib (n=237)

  • Efficacy

    ORR:78% [68-85]
    mDoR: 13.4 mos [9.4-23.1]

  • Safety

    Grade≥ 3: Neutropenia (19%), hypertension (11l%), lymphopenia (5%)
    • https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023